Long Shortz with Rhythm: Otto Buttula reflects, Gavin Fox-Smith steps up

Rhythm Biosciences outgoing chair and chair elect discuss the company’s strategy moving forward after leadership changes.

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) as the company undergoes a leadership transition, with outgoing Chair Otto Buttula reflecting on his tenure.

Buttula paid a crucial role in overseeing RHY's proteomic platform expansion into other cancers and the rebuilding of the ColoSTAT kit program into a more useable commercial product.

Chair-elect Gavin Fox-Smith also joins the interview, sharing his excitement about advancing the company's early cancer detection technologies.

Watch the video to learn more.

This video was developed in collaboration with Rhythm Biosciences, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Rhythm: Otto Buttula reflects, Gavin Fox-Smith steps up